DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Bladder Cancer, Malignant Melanoma, Non-Small-Cell Lung Cancer, Renal Cell Carcinoma (TBC) | Access and Reimbursement | US | 2016
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…